ERBB2 and neoplasm: In the case of 99mTc-labeled sdAb NM-02 [18], a number of clinically HER2-negative tumors had higher SUV values than HER2-positive in the Phase I clinical study, i.e., the tumor uptake did not match the expression level of HER2.